Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07105488 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis (AD), sponsored by Bluefin Biomedicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
- 7
- Study locations
NCT07105488: Recruiting Phase 2 study of Atopic Dermatitis (AD), sponsored by Bluefin Biomedicine.
NCT07105488 is a Phase 2 study of Atopic Dermatitis (AD) that is actively recruiting participants, run by Bluefin Biomedicine. The registered enrollment target is 225 participants, above the 78-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (188% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07105488, a Phase 2 study of Atopic Dermatitis (AD), is actively recruiting participants, sponsored by Bluefin Biomedicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Primary Outcome
To evaluate the efficacy of BFB759 in adult male and female participants with AD as assessed by Eczema Area and Severity Index (EASI) score. Measure improvements in redness, swelling, scratching damage, and roughness.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL BFB759
Study Locations (7)
Florida
- Ziaderm Research LLC - North Miami Beach
- Conquest Research LLC - Winter Park
California
- Antelope Valley Clinical Trials - Lancaster
Louisiana
- Clinical Trials Management, LLC - Metairie
New York
- Vitality Clinical Trials LLC - Woodbury
Ohio
- Apex Clinical Research Center, LLC - Mayfield Heights
Texas
- Stryde Research-Epiphany Dermatology - Southlake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
What NCT07105488 shows while recruiting
NCT07105488 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, above the 78-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (188% higher).
The record links to 1 condition, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07105488 lists 7 locations in 6 states (Florida, California, Louisiana).
Frequently Asked Questions
What is clinical trial NCT07105488 about?
NCT07105488 is a clinical study titled "A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis". This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
What is the current status of trial NCT07105488?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2025-07-15. Estimated completion is 2027-03-31.
What conditions does trial NCT07105488 study?
This clinical trial studies the following conditions: Atopic Dermatitis (AD).
What interventions are being tested in trial NCT07105488?
The interventions under investigation include: Placebo (DRUG), BFB759 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07105488?
This trial is sponsored by Bluefin Biomedicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07105488 being conducted?
This trial has 7 study locations across California, Florida, Louisiana, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
RECRUITING · Phase 2
-
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
RECRUITING · Phase 1
-
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
RECRUITING · Phase 1
-
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
RECRUITING · Phase 1
-
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI